NASDAQ: ELDN
Eledon Pharmaceuticals Inc Stock Forecast, Predictions & Price Target

Be the first to know when Wall Street analysts revise their ELDN stock forecasts and price targets.

Forecast return on equity

Is ELDN forecast to generate an efficient return?

Company
-62.19%
Industry
140.91%
Market
90.47%
ELDN's Return on Equity is... subscribe to Premium to read more.
Forecast High Return on Equity Forecast

Forecast return on assets

Is ELDN forecast to generate an efficient return on assets?

Company
-44.18%
Industry
32.45%
ELDN is forecast to generate... subscribe to Premium to read more.
Forecast Return on Assets vs Industry Forecast

ELDN earnings per share forecast

What is ELDN's earnings per share in the next 3 years based on estimates from 3 analysts?

Avg 1 year Forecast
-$0.92
Avg 2 year Forecast
-$0.92
Avg 3 year Forecast
-$1.25

ELDN revenue forecast

What is ELDN's revenue in the next 3 years based on estimates from 1 analyst?

Avg 1 year Forecast
$17.4M
Avg 2 year Forecast
$109.0M
Avg 3 year Forecast
$193.0M

ELDN vs Biotech Stocks

TickerPricePrice TargetUp/downsideConsensus
ELDN$2.87N/AN/A
TLSA$1.55N/AN/A
ALMS$3.14$19.00+505.10%Strong Buy
ENGN$3.33$22.00+560.66%Buy
ACTU$8.65$20.00+131.21%Buy

Eledon Pharmaceuticals Stock Forecast FAQ

What is ELDN's earnings growth forecast for 2025-2027?

(NASDAQ: ELDN) Eledon Pharmaceuticals's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 10.6%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 15.33%.

Eledon Pharmaceuticals's earnings in 2025 is -$38,708,000.On average, 3 Wall Street analysts forecast ELDN's earnings for 2025 to be -$55,288,843, with the lowest ELDN earnings forecast at -$62,277,046, and the highest ELDN earnings forecast at -$51,498,327. On average, 2 Wall Street analysts forecast ELDN's earnings for 2026 to be -$55,091,233, with the lowest ELDN earnings forecast at -$59,881,775, and the highest ELDN earnings forecast at -$50,300,691.

In 2027, ELDN is forecast to generate -$74,852,219 in earnings, with the lowest earnings forecast at -$74,852,219 and the highest earnings forecast at -$74,852,219.

If you're new to stock investing, here's how to buy Eledon Pharmaceuticals stock.

What is ELDN's revenue growth forecast for 2028-2030?

(NASDAQ: ELDN) Eledon Pharmaceuticals's forecast annual revenue growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 56.38%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 9.68%.

Eledon Pharmaceuticals's revenue in 2025 is $0.On average, 1 Wall Street analysts forecast ELDN's revenue for 2028 to be $1,041,942,885, with the lowest ELDN revenue forecast at $1,041,942,885, and the highest ELDN revenue forecast at $1,041,942,885. On average, 1 Wall Street analysts forecast ELDN's revenue for 2029 to be $6,527,113,475, with the lowest ELDN revenue forecast at $6,527,113,475, and the highest ELDN revenue forecast at $6,527,113,475.

In 2030, ELDN is forecast to generate $11,557,182,575 in revenue, with the lowest revenue forecast at $11,557,182,575 and the highest revenue forecast at $11,557,182,575.

What is ELDN's forecast return on assets (ROA) for 2025-2028?

(NASDAQ: ELDN) forecast ROA is -44.18%, which is lower than the forecast US Biotechnology industry average of 32.45%.

What is ELDN's Earnings Per Share (EPS) forecast for 2025-2027?

(NASDAQ: ELDN) Eledon Pharmaceuticals's current Earnings Per Share (EPS) is -$0.97. On average, analysts forecast that ELDN's EPS will be -$0.92 for 2025, with the lowest EPS forecast at -$1.04, and the highest EPS forecast at -$0.86. On average, analysts forecast that ELDN's EPS will be -$0.92 for 2026, with the lowest EPS forecast at -$1.00, and the highest EPS forecast at -$0.84. In 2027, ELDN's EPS is forecast to hit -$1.25 (min: -$1.25, max: -$1.25).

What is ELDN's forecast return on equity (ROE) for 2025-2028?

(NASDAQ: ELDN) forecast ROE is -62.19%, which is considered weak.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.